The tumor progression was significantly improved in mice that were treated with both PD-1 blockade and CBM588 when compared to what observed in control mice that solely received anti-PD-1 antibodies (Figure 1B and Supplementary Figure S1). Here, PDCD1 is linked to neoplasm.